API | givosiran

givosiran (Givlaari) Report issue

Biologics Nucleic acid Orphan Drug ^FDA Approved ^FDA First in Class Priority Review ^FDA

AACT

Active Ingredient History

NOW

Givosiran, sold under the brand name Givlaari, is a medication used for the treatment of adults with acute hepatic porphyria. Givosiran is a small interfering RNA (siRNA) directed towards delta-aminolevulinate synthase 1 (ALAS1), an important enzyme in the production of heme. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

givosiran

givosiran sodium

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Missing data
Pro Drug: No

Drug Pricing (per unit)

United States

$29087.8700 - $38412.0600

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

aln-as1

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (2)

Porphyria, Acute Intermittent (approved 2019)

Porphyrias, Hepatic

Experimental Indications - Clinical Trial Phases 1-4 (2)

Porphyria, Acute Intermittent (Phase 3)

Porphyrias (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue